Sign up USA
Proactive Investors - Run By Investors For Investors

SpectraScience says Oncoscope tech is complementary

Medical device and cancer diagnostic group SpectraScience has acquired the assets of North Carolina firm Oncoscope, it said.
SpectraScience says Oncoscope tech is complementary
Oncoscope has developed a proprietary optical imaging system to provide immediate detection of pre-cancerous epithelial tissues using scattered white light.

Medical device and cancer diagnostic group SpectraScience (OTCQB: SCIE) has acquired the assets of North Carolina firm Oncoscope, it said.

Oncoscope has developed a proprietary optical imaging system to provide immediate detection of pre-cancerous epithelial tissues using scattered white light.

Their first target indication was for Barrett's Esophagus -  a precursor for cancer of the esophagus.

Michael Oliver, president and chief executive of SpectraScience, told investors: "The oncoscope technology is the perfect complement to ours.

"SpectraScience's Laser Induced Fluorescence Spectroscopy (LIFS) measures concentration of specific biomarkers in epithelial tissues.

"The strength of Oncoscope's technology is its focus on enlarged cell nuclei, an early marker of pre-cancers and cancers.

"Both technologies arrive at the same conclusion by measuring different indicators. Having two complementary technologies allows us to address multiple types of cancers including both esophageal and colon cancers."

He added: "Oncoscope's focus on a diagnostic for Barrett's Esophagus will shorten the development time for a commercial product to address this indication. With a solution for diagnosis of cancer in the upper GI as well as the lower GI, we will be able to more efficiently utilize our manufacturing capabilities and leverage the sales channel to Gastroenterologists."

Protected by more than 30 patents in 28 countries, covering fundamental elements of the technology, the SpectraScience's WavSTAT Optical Biopsy System uses light to optically scan tissue and provide the physician with an immediate analysis.

With FDA approval for sale in the US and the CE Mark for the European Union, the WavSTAT System is the first commercially available product that incorporates this innovative patent protected technology for clinical use.

View full SCIE profile View Profile

SpectraScience Timeline

Related Articles

1-Operation.jpg
January 18 2017
Deltex’s overseas sales are booming but its previously dominant NHS revenues are dropping off
the word antioxidant
August 15 2017
The heparin test is the firm’s lead product; however the company’s OxiChek device for oxidative stress is also gaining traction
man at a micrscope
September 29 2017
The company is a specialist in the storage of stems cells from the umbilical cord, which could provide a potentially life-saving treatment for 82 blood-borne diseases

No investment advice

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is suitable or advisable for any specific person. You understand that the Company receives either monetary or securities compensation for our services. We stand to benefit from any volume this write-up may generate.

You further understand that none of the information providers or their affiliates will advise you personally concerning the nature, potential, advisability, value or suitability of any particular security, portfolio of securities, transaction, investment strategy, or other matter.

You understand that the Site may contain opinions from time to time with regard to securities mentioned in other products, including company related products, and that those opinions may be different from those obtained by using another product related to the Company. You understand and agree that contributors may write about securities in which they or their firms have a position, and that they may trade such securities for their own account. In cases where the position is held at the time of publication and such position is known to the Company, appropriate disclosure is made. However, you understand and agree that at the time of any transaction that you make, one or more contributors may have a position in the securities written about. You understand that price and other data is supplied by sources believed to be reliable, that the calculations herein are made using such data, and that neither such data nor such calculations are guaranteed by these sources, the Company, the information providers or any other person or entity, and may not be complete or accurate.

From time to time, reference may be made in our marketing materials to prior articles and opinions we have published. These references may be selective, may reference only a portion of an article or recommendation, and are likely not to be current. As markets change continuously, previously published information and data may not be current and should not be relied upon.

Copyright © Proactiveinvestors.com, 2017. All Rights Reserved - Proactive Investors North America Inc., Proactive Investors LLC

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use